VRTX241108C620000
- 0.00
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Form 144 | Vertex Pharmaceuticals(VRTX.US) Officer Proposes to Sell 7.83 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 8, $Vertex Pharmaceuticals(VRTX.US)$ Officer Kewalramani Reshma intends to sell 15,198 shares of its common stock on Nov 8, with a total market value of approximately $7.83
Vertex Pharmaceuticals Faces Integration Challenges in Alpine Acquisition
Argus Raises Price Target on Vertex Pharmaceuticals to $550 From $530
Vertex Pharmaceuticals Price Target Raised to $408.00/Share From $361.00 by Canaccord Genuity
J.P. Morgan Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $503
CCORF Maintains Vertex Pharmaceuticals(VRTX.US) With Sell Rating, Raises Target Price to $408
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $486 to $600
Vertex Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
Vertex Pharmaceuticals: Strong Financial Performance and Innovative Drug Pipeline Underpin Buy Rating
Cautious Outlook: Evaluating Vertex Pharmaceuticals' Growth Potential Amidst Strong Performance and Speculative Risks
Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
Vertex Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Sector Update: Health Care Stocks Rise Tuesday Afternoon
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity
Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000: What's Driving Markets Tuesday?
Top Midday Stories: Boeing Workers Approve Labor Contract, End Strike; Palantir Raises FY Revenue Guidance
RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $451
Vertex Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Issued FY24 Product Revenue Guidance Above Estimates. Also, Morgan Stanley Maintained an Equal-Weight Rating on the Stock and...
Express News | Vertex Pharmaceuticals Inc : Canaccord Genuity Raises Target Price to $408 From $361
Vertex Pharmaceuticals on Pace for Largest Percent Increase Since December 2023 -- Data Talk